REG-Arix Bioscience PLC Investment team changes

Arix BioscienceAnnouncement

18/01/2021 07:05

============

   Arix Bioscience PLC (ARIX)
   Investment team changes

   18-Jan-2021 / 07:00 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

    

                              Arix Bioscience plc

                                        

                            Investment team changes

    

   LONDON, 18 January 2021: Arix Bioscience plc ("Arix", LSE: ARIX) a  global
   venture capital  company focused  on investing  and building  breakthrough
   biotech companies, today announces that Jonathan Tobin, PhD, has  resigned
   as Managing Director to pursue  another opportunity. His resignation  will
   be effective from 1 March.

    

   Naseem Amin, MD, Executive Chairman of Arix, commented: "On behalf of  the
   Board and the  investment team,  I would like  to thank  Jonathan for  his
   contribution to the development of Arix since its inception. Our portfolio
   companies, particularly where  he was the  Investment Director,  benefited
   greatly from  his counsel  and contribution  to their  progress.  Jonathan
   departs with  our very  best wishes.  Following a  successful 2020,  I  am
   confident we  have  the investment  team  to continue  management  of  our
   current portfolio and source new opportunities.  We will be expanding  our
   investment team both in the US and London as we continue to deploy capital
   into new opportunities."

    

   Jonathan Tobin, PhD, added:  "It has been  an honour to  work with such  a
   high quality team and  portfolio of innovative companies,  led by some  of
   the most  successful scientists  and entrepreneurs  in biotech.  Arix  has
   grown significantly since  its inception  and built a  broad portfolio  of
   companies,  each  with  the  potential  to  bring  important  breakthrough
   therapies to patients. These companies  are expected to reach  significant
   clinical milestones in the near and medium term and all have potential  to
   generate substantial value for Arix shareholders."

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   Charlotte Parry, Head of Investor Relations

   +44 (0)20 7290 1072

    1 charlotte@arixbioscience.com

    

   Optimum Strategic Communications

   Supriya Mathur, Shabnam Bashir, Manel Mateus

   +44 (0)20 3922 1906

    2 optimum.arix@optimumcomms.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing  in   and  building   breakthrough  biotech   companies   around
   cutting-edge advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise  and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  3 www.arixbioscience.com

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCH
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   91645
   EQS News ID:    1161160


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1161160&application_name=news&site_id=refinitiv

References

   Visible links
   1. mailto:charlotte@arixbioscience.com
   2. mailto:optimum.arix@optimumcomms.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1161160&site_id=refinitiv&application_name=news


============